Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Attracting 60,000 Adalimumab Patients Aids Biogen

Biogen’s Total Year-To-Date Biosimilar Sales Top $500m

Executive Summary

Rolling out its Imraldi adalimumab brand across Europe is maintaining growth in Biogen’s biosimilars franchise as sales of its Benepali etanercept drug slip back.

You may also be interested in...



Samsung Bioepis Adds To Biogen Collaboration

Samsung Bioepis and Biogen have agreed a marketing deal for ‘next generation’ biosimilars aflibercept and ranibizumab in the US, Canada, Europe, Japan and Australia, as well as providing an option for Biogen to extend its existing deal to market anti-TNF biosimilars adalimumab, etanercept and infliximab in Europe and adding a further option for rights to sell these three biosimilars in China.

No Single Biosimilars Model Fits Europe, Says Samsung Bioepis’ Ko

In the second part of an exclusive interview with Generics Bulletin, Samsung Bioepis CEO Christopher Hansung Ko sets out the firm’s strategy in Europe, as well as the importance of Brazil and China to its future plans.

Samsung Bioepis’ Adalimumab Has A Longer Life Out Of The Fridge

Samsung Bioepis’ Imraldi adalimumab biosimilar has been granted a European label update that approves the product to be stored in non-refrigerated conditions for up to 28 days.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB149283

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel